Skip to main content
SpringerLink
Log in

Effects of intravenous fenoldopam (SK&F 82526-J) on blood pressure in severe hypertension

  • Letter to the Editor
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hughes A, Thom S, Martin G, et al. The action of a dopamine (DA1) receptor agonist, fenoldopam, in human vasculature in vivo and in vitro. Br J Clin Pharmacol 1986;22:535–540.

    Google Scholar 

  2. Lokhandwala MF. Preclinical and clinical studies on the cardiovascular and renal effects of fenoldopam: A DA-1 receptor agonist. Drug Develop Res 1987;10:123–134.

    Google Scholar 

  3. Lokhandwala MF, Watkins HO, Sabouni MH, Alkadhi KA Pharmacological analysis of the actions of SK&F 82526 on cardiovascular dopamine receptors. J Pharmacol Exp Ther 1985;234:337–344.

    Google Scholar 

  4. Harvey JN, Worth DP, Brown J, Lee MR. The effect of oral fenoldopam (SK&F 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br J Clin Pharmacol 1985;19:21–27.

    Google Scholar 

  5. Weber RR, McCoy CE, Ziemniak JA, et al. Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. Br J Clin Pharmacol 1988;25:17–21.

    Google Scholar 

  6. Ventura HO, Messerli FH, Frohlich ED, et al. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation 1984;69:1142–1145.

    Google Scholar 

  7. Caruana MP, Heber M, Brigden G, Raftery EB. Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension. Br J Clin Pharmacol 1987;24:721–727.

    Google Scholar 

  8. Harvey JN, Worth DP, Brown J, Lee MR. Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. Br J Clin Pharmacol 1986;21:53–61.

    Google Scholar 

  9. White WB, Radford MJ, Gonzalez FM, et al. Selective dopamine-1 agonist therapy in severe hypertension: Effects of intravenous fenoldopam. J Am Coll Cardiol 1988;11: 1118–1123/

    Google Scholar 

  10. White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med 1989;149:870–874.

    Google Scholar 

  11. Ruilope LM, Robles RG, Miranda B, et al. Renal effects of fenoldopam in refractory hypertension. J Hypertens 1988;6:665–669.

    Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    SK&F Fenoldopam Working Group

    Additional information

    Address for correspondence and reprint requests: Dr. Elisabetta Riva, Clinical Development Director, Smith Kline & French S.p.A., Viale Ortles 12, 20139 Milan, Italy.

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    SK&F Fenoldopam Working Group. Effects of intravenous fenoldopam (SK&F 82526-J) on blood pressure in severe hypertension. Cardiovasc Drug Ther 6, 445–446 (1992). https://doi.org/10.1007/BF00054195

    Download citation

    • Issue Date:

    • DOI: https://doi.org/10.1007/BF00054195

    Key Words

    Search

    Navigation